Invasive Basal Cell Carcinoma of the Skin Treated Successfully with Vismodegib: A Case Report
| Autor: | Juan Camilo Barreto Andrade, Fade Mahmoud, Ramez Awad, Heba A. M. Mousa |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Shoulder medicine.medical_specialty Skin Neoplasms Pyridines Vismodegib Antineoplastic Agents Disease Lesion 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Positron Emission Tomography Computed Tomography Biopsy medicine Carcinoma Humans Anilides Basal cell carcinoma Aged medicine.diagnostic_test business.industry General Medicine medicine.disease Hedgehog signaling pathway Carcinoma Basal Cell 030220 oncology & carcinogenesis Radiology Clinical Medicine Skin cancer medicine.symptom business medicine.drug |
| Zdroj: | The Permanente Journal. 22 |
| ISSN: | 1552-5775 1552-5767 |
| Popis: | Introduction Basal cell carcinoma (BCC) is the most common skin cancer. It is primarily a local disease, and it very rarely causes metastatic disease. Chemotherapeutic agents had limited success in management of metastatic disease until the introduction of vismodegib. In this case report, we describe the presentation of a metastatic BCC that was not amenable to surgical resection or local treatment options and was treated successfully with vismodegib. Case presentation A 69-year-old white man was referred to our surgical clinic for evaluation of an erosive left shoulder lesion. Biopsy in the clinic showed BCC with evidence of metastases on positron emission tomography-computed tomography scan. Tumors had invaded multiple bony structures and multiple organs, making surgical resection not an option. The decision was made to treat the patient with vismodegib. At 1-year follow-up, the patient's left shoulder lesion had improved with no evidence of metabolically active distant metastasis. Discussion Although BCC is the most common skin cancer, it is usually a local disease and treated with local measures. Metastatic BCC is extremely rare, and in cases when surgical resection or local radiation are not viable options, chemotherapeutic agents typically offer very limited improvement. Vismodegib is an oral selective sonic hedgehog pathway inhibitor that shows benefit in patients with locally advanced or metastatic disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|